In mice, XPO1 occupancy saturation at ∼10 mg/kg (∼50 mg flat dose in humans) is consistent a dose that shows anti-cancer activity in patients with heavily pretreated hematologic and solid tumors [8, 9, 18]. The gene discussed is XPO1; the disease is cancer.